Global Merck & Co., Inc., Kenilworth, NJ, USA news: 

Click here to access our global newsroom 

MSD local news: 

20.04.2017 KEYTRUDA® registered for treatment of lung cancer
April 20, 2017, Merck Sharp & Dohme Limited (MSD) today announced KEYTRUDA® (pembrolizumab) has now received its second Medsafe registration for lung cancer. ​ 

14.12.2016 New medicine to fight Hepatitis C now registered
15 December 2016, Merck Sharp & Dohme (New Zealand) Ltd (MSD) today announced ZEPATIER® (elbasvir/grazoprevir) has been registered by Medsafe for the treatment of chronic Hepatitis C – genotype 1, 3* and 4 infection in adults 

28.06.2016 MSD signs KEYTRUDA agreement and offers bridging programme
MSD MSD has signed a provisional agreement with PHARMAC (subject to stakeholder consultation and PHARMAC board approval) to fund MSD’s anti-PD1 immunotherapy KEYTRUDA® (pembrolizumab) for the treatment of advanced melanoma that has spread. 

28.06.2016 KEYTRUDA now registered to treat lung cancer
August 29th 2016, MSD today announced that its anti-PD1 immunotherapy KEYTRUDA® (pembrolizumab) has been registered byMedsafe for New Zealand patients who have previously been treated for advanced non-smallcell lung cancer (NSCLC) and whose tumours express the PD-L1 biomarker. 

07.09.2015 New Medicine to fight melanoma now registered
MSD New Zealand today announced that its anti-PD1 immunotherapy KEYTRUDA® (pembrolizumab) has been registered by MEDSAFE for the treatment of the most deadly form of skin cancer – advanced metastatic melanoma 

03.08.2015 New Zealand Doctors Can Now Access Univadis
New Zealand doctors now have access to Univadis, a free medical education and unbiased health information website for healthcare professionals. 

31.07.2015 Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year
Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet. 

24.06.2014 Good News For Babies - Funded Gastroenteritis Vaccine Nearly Here!
Soon babies born in New Zealand will be eligible for funded vaccination against rotavirus gastroenteritis caused by rotavirus infection. PHARMAC has funded ROTATEQ® (rotavirus vaccine, live, oral, pentavalent) and added it to the Immunisation Schedule from July 1st. But parents of young babies should be booking their first vaccination visit now as timing for the three-dose vaccine is very important. 

02.12.2013 New Zealand women now have access to the new once monthly vaginal ring
For women who don’t want the hassle of a daily contraceptive, there is now a new once monthly contraception option – Nuvaring (120mcg etonogestrel / 15mcg ethinyl per day). 

22.08.2013 Newly funded Hepatitis C treatment will help curb New Zealand's silent epidemic
From the 1st of September hepatitis C sufferers will have a new treatment option thanks to VICTRELISTM (boceprevir) being funded for people with chronic viral hepatitis C, genotype 1. 

14.02. 2013 More New Zealanders Die of Cardiovascular Disease Than Cancer, Diabetes and Infectious Diseases Combined
You may be aware it is Heart Week 2013 (11-17 February) - but did you know that more New Zealanders are dying of cardiovascular disease than cancer, diabetes and infectious diseases combined according to statistics from the Ministry of Health. 

01.08.2012 - Asthma Patients Get Another Fully Funded Treatment Option
New Zealand asthma patients will now have another fully funded treatment option thanks to Pharmac reimbursing SINGULAIR® (montelukast sodium) from 1 August 2012.


​For Media enquires, please contact:

Sheryl Kurte
External Affairs Manager
Phone: +64 21 281 7584